Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies.

ABSTRACT:

Purpose

Hypereosinophilia represents a heterogenous group of severe medical conditions characterized by elevated numbers of eosinophil granulocytes in peripheral blood, bone marrow or tissue. Treatment options for hypereosinophilia remain limited despite recent approaches including IL-5-targeted monoclonal antibodies and tyrosine kinase inhibitors.

Methods

To understand aberrant survival patterns and options for pharmacologic intervention, we characterized BCL-2-regulated apoptosis signaling by testing for BCL-2 family expression levels as well as pharmacologic inhibition using primary patient samples from diverse subtypes of hypereosinophilia (hypereosinophilic syndrome n = 18, chronic eosinophilic leukemia not otherwise specified n = 9, lymphocyte-variant hypereosinophilia

SUBMITTER: Odinius TO 

PROVIDER: S-EPMC8800915 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature